OncoMatch/Clinical Trials/NCT05962502
Cetuximab Plus Irinotecan in Patients With NeoRAS Wild-type Metastatic Colorectal Cancer In Third-line Therapy
Is NCT05962502 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies Cetuximab and irinotecan for metastatic colorectal cancer.
Treatment: Cetuximab and irinotecan — This is a single-arm, open-label, phase II clinical trial. The goal of this study is to evaluate the efficacy and safety of cetuximab plus irinotecan in patients with NeoRAS wild-type primary left-sided mCRC in third-line therapy.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Targeted therapy
Cancer type
Colorectal Cancer
Biomarker criteria
Required: KRAS wild-type
Blood-based ctDNA testing shows that both RAS and BRAF genes are wild-type after second-line therapy progression
Required: NRAS wild-type
Blood-based ctDNA testing shows that both RAS and BRAF genes are wild-type after second-line therapy progression
Required: HRAS wild-type
Blood-based ctDNA testing shows that both RAS and BRAF genes are wild-type after second-line therapy progression
Required: BRAF wild-type
Blood-based ctDNA testing shows that both RAS and BRAF genes are wild-type after second-line therapy progression
Excluded: MMR deficient
dMMR/MSI-H mCRC [excluded]
Excluded: MSH2 MSI-H
dMMR/MSI-H mCRC [excluded]
Disease stage
Metastatic disease required
objectively measurable lesions according to RECIST v1.1 criteria
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: fluorouracil compound
previously treated with fluorouracil compounds
Must have received: oxaliplatin
previously treated with oxaliplatin
Must have received: irinotecan
previously treated with irinotecan
Lab requirements
Blood counts
platelets > 90 × 10^9/L; leukocytes > 3 × 10^9/L; neutrophils > 1.5 × 10^9/L; hemoglobin > 8.0g/100ml
Kidney function
Serum creatinine < 1.5 x ULN, or calculated creatinine clearance ≥ 50 ml/min (using the Cockcroft Gault formula)
Liver function
Serum bilirubin ≤ 1.5 x ULN and transaminases ≤ 5 x ULN; Liver function: Child-Push score: Class A
Normal hematologic function (platelets > 90 × 10^9/L; leukocytes > 3 × 10^9/L; neutrophils > 1.5 × 10^9/L; hemoglobin > 8.0g/100ml). Serum bilirubin ≤ 1.5 x ULN and transaminases ≤ 5 x ULN. Liver function: Child-Push score: Class A. Serum creatinine < 1.5 x ULN, or calculated creatinine clearance ≥ 50 ml/min (using the Cockcroft Gault formula).
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT05962502 currently recruiting?
Yes, this trial is currently recruiting patients.
Is prior treatment required for enrollment?
Yes. Patients must have previously received fluorouracil compound and oxaliplatin.
Does this trial require KRAS?
Yes, KRAS wild-type is a required biomarker for enrollment.
Does this trial require NRAS?
Yes, NRAS wild-type is a required biomarker for enrollment.
Does this trial require HRAS?
Yes, HRAS wild-type is a required biomarker for enrollment.
Are patients with MMR alterations eligible?
No. MMR deficient is an exclusion criterion.
Are patients with MSH2 alterations eligible?
No. MSH2 MSI-H is an exclusion criterion.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages